166 related articles for article (PubMed ID: 33635593)
21. Emergency department management of chemotherapy related febrile neutropenia: An opportunity to improve care.
Pettit N; Boadu D; Bischof JJ
Am J Emerg Med; 2021 Dec; 50():5-9. PubMed ID: 34265732
[TBL] [Abstract][Full Text] [Related]
22. [Prognosis prediction of febrile neutropenia by MASCC score: A retrospective study].
Cervetti L; Vallard A; Le Moulec S; Espenel S; Falk AT; Ben Mrad M; Guy JB; Diao P; Méry B; Langrand-Escure J; Ferrand FR; Rivoirard R; Ceccaldi B; Védrine L; Magné N; Chargari C
Bull Cancer; 2016 Jun; 103(6):561-70. PubMed ID: 27181759
[TBL] [Abstract][Full Text] [Related]
23. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
[TBL] [Abstract][Full Text] [Related]
24. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.
Carmona-Bayonas A; Jiménez-Fonseca P; Virizuela Echaburu J; Antonio M; Font C; Biosca M; Ramchandani A; Martínez J; Hernando Cubero J; Espinosa J; Martínez de Castro E; Ghanem I; Beato C; Blasco A; Garrido M; Bonilla Y; Mondéjar R; Arcusa Lanza MÁ; Aragón Manrique I; Manzano A; Sevillano E; Castañón E; Cardona M; Gallardo Martín E; Pérez Armillas Q; Sánchez Lasheras F; Ayala de la Peña F
J Clin Oncol; 2015 Feb; 33(5):465-71. PubMed ID: 25559804
[TBL] [Abstract][Full Text] [Related]
25. Validation of the Clinical Index of Stable Febrile Neutropenia (CISNE) model in febrile neutropenia patients visiting the emergency department. Can it guide emergency physicians to a reasonable decision on outpatient vs. inpatient treatment?
Moon H; Choi YJ; Sim SH
PLoS One; 2018; 13(12):e0210019. PubMed ID: 30596803
[TBL] [Abstract][Full Text] [Related]
26. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study.
Ahmed N; El-Mahallawy HA; Ahmed IA; Nassif S; El-Beshlawy A; El-Haddad A
Pediatr Blood Cancer; 2007 Nov; 49(6):786-92. PubMed ID: 17366527
[TBL] [Abstract][Full Text] [Related]
27. Clinical analysis of febrile neutropenia in urological anticancer chemotherapy: retrospective single center study.
Nishiyama N; Takahashi S; Mizuno T; Uehara T; Hashimoto J; Kurimura Y; Masumori N
Int J Clin Oncol; 2015 Oct; 20(5):1012-7. PubMed ID: 25652906
[TBL] [Abstract][Full Text] [Related]
28. Outpatient therapy for febrile neutropenia.
Innes H; Marshall E
Curr Opin Oncol; 2007 Jul; 19(4):294-8. PubMed ID: 17545790
[TBL] [Abstract][Full Text] [Related]
29. Time to antibiotics and outcomes in cancer patients with febrile neutropenia.
Perron T; Emara M; Ahmed S
BMC Health Serv Res; 2014 Apr; 14():162. PubMed ID: 24716604
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department.
García de Guadiana-Romualdo L; Cerezuela-Fuentes P; Español-Morales I; Esteban-Torrella P; Jiménez-Santos E; Hernando-Holgado A; Albaladejo-Otón MD
Biochem Med (Zagreb); 2019 Feb; 29(1):010702. PubMed ID: 30591812
[TBL] [Abstract][Full Text] [Related]
31. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
[TBL] [Abstract][Full Text] [Related]
32. A novel approach to improving ambulatory outpatient management of low risk febrile neutropenia: an Enhanced Supportive Care (ESC) clinic.
Cooksley T; Campbell G; Al-Sayed T; LaMola L; Berman R
Support Care Cancer; 2018 Sep; 26(9):2937-2940. PubMed ID: 29675545
[TBL] [Abstract][Full Text] [Related]
33. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies.
Cherif H; Johansson E; Björkholm M; Kalin M
Haematologica; 2006 Feb; 91(2):215-22. PubMed ID: 16461306
[TBL] [Abstract][Full Text] [Related]
34. Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event.
Rivas-Ruiz R; Villasis-Keever M; Miranda-Novales G; Castelán-Martínez OD; Rivas-Contreras S
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD009031. PubMed ID: 30887505
[TBL] [Abstract][Full Text] [Related]
35. Can MASCC and CISNE scores predict delays of lung cancer chemotherapy after febrile neutropenia?
Ono Y; Hayama N; Hattori S; Ito Y; Oguma T; Sakamaki F; Asano K
Thorac Cancer; 2022 Dec; 13(24):3504-3509. PubMed ID: 36330990
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of complete blood count parameters to predict poor outcomes in cancer patients with febrile neutropenia presenting to the emergency department.
Choi A; Park I; Lee HS; Chung J; Kim MJ; Park YS
Ann Med; 2022 Dec; 54(1):599-609. PubMed ID: 35175159
[TBL] [Abstract][Full Text] [Related]
37. Impact of time to antibiotic on hospital stay, intensive care unit admission, and mortality in febrile neutropenia.
Daniels LM; Durani U; Barreto JN; O'Horo JC; Siddiqui MA; Park JG; Tosh PK
Support Care Cancer; 2019 Nov; 27(11):4171-4177. PubMed ID: 30805726
[TBL] [Abstract][Full Text] [Related]
38. Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.
Girmenia C; Russo E; Carmosino I; Breccia M; Dragoni F; Latagliata R; Mecarocci S; Morano SG; Stefanizzi C; Alimena G
Ann Hematol; 2007 Apr; 86(4):263-70. PubMed ID: 17225113
[TBL] [Abstract][Full Text] [Related]
39. Advances in management of low-risk febrile neutropenia.
Teuffel O; Sung L
Curr Opin Pediatr; 2012 Feb; 24(1):40-5. PubMed ID: 22037219
[TBL] [Abstract][Full Text] [Related]
40. Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients.
de Souza Viana L; Serufo JC; da Costa Rocha MO; Costa RN; Duarte RC
Support Care Cancer; 2008 Jul; 16(7):841-6. PubMed ID: 17960431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
